Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
16 evidence topics · 12 sources
Palazestrant phase 2 results by ESR1 status at 120 mg (OP-1250-001)
Palazestrant results by ESR1 status in the second- and third-line subset (OP-1250-001)
Palazestrant plus ribociclib by ESR1 status after a prior CDK4/6 inhibitor (OP-1250-003)
Investigator interpretation of ESR1-dependent benefit across the class
“Recent studies showed that imlunestrant may be beneficial only for cancers harboring ESR1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Elacestrant in tumors without a detected ESR1 mutation (EMERALD, FDA review)
“In an exploratory analysis of PFS in the ESR1-mut-nd subgroup, the HR was 0.86 (95% CI, 0.63 to 1.19), with the median PFS of 1.9 months (95% CI, 1.9 to 3.6) in the elacestrant arm and 2.0 months (95% CI, 1.9 to 2.2) in the SOC arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant by ESR1 status (EMBER-3)
“In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, the treatment effect of imlunestrant–abemaciclib was similar in patients with or without ESR1 or PI3K pathway mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vepdegestrant by ESR1 status (VERITAC-2)
“Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with ER-positive, HER2-negative advanced breast cancer, vepdegestrant was associated with significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations but not in the full patient population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Giredestrant plus everolimus by ESR1 status (evERA)
“Among 207 patients with ESR1 -mutated tumors, median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Consistency of oral SERD hazard ratios in ESR1-mutated tumors
Duration of prior endocrine therapy plus CDK4/6 inhibitor (EMERALD)
“In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The P value for interaction between elacestrant treatment and prior ET+CDK4/6i duration (<12 vs. ≥12 months) was statistically significant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior ET+CDK4/6i ≥12 months may help identify patients with ESR1-mutated tumors that remain endocrine-sensitive to elacestrant, enabling ET sequencing in the second line before other targeted therapies and drug combinations, and may delay chemotherapy-based regimens, including antibody–drug conjugates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concurrent ESR1 and PI3K pathway mutations with elacestrant in routine practice
“Disease with dual ESR1 and PI3K pathway mutations (PIK3CA, AKT1, and PTEN) had a median TTNT of 5.2 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher ESR1 polyclonality (≥4 alterations; 11% of patients) correlated with a shorter TTNT of 5.2 months (hazard ratio, 1.44; 95% confidence interval, 1.01–2.06), but efficacy was consistent across ESR1 alleles (e.g., Y537S and D538G).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visceral and bone metastases (EMERALD)
“ESR1 mutations are associated with visceral metastases and endocrine resistance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visceral and liver metastases with elacestrant in routine practice
“In patients with coexisting ESR1- and PI3K-pathway–mutated tumors, mTTNT was 6.3 months (95% CI, 4.8–7.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“mTTNT was 7.9 months (95% CI, 7.1–9.8) in all patients and was also sustained in patients with no prior fulvestrant [12.9 months (95% CI, 7.2–not reached)], no prior chemotherapy [8.4 months (95% CI, 7.1–13.3)], visceral metastasis [7.9 months (95% CI, 7.0–9.9)], and liver metastases [7.2 months (95% CI, 6.3–9.0)].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Abemaciclib plus fulvestrant across ESR1 and PIK3CA subgroups (postMONARCH)
“Consistent abemaciclib treatment effect was observed across the most prevalent biomarker subgroups” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HR, 0.79 (95% CI, 0.54 to 1.15) ESR1 detected versus 0.78 (95% CI, 0.54 to 1.12) not detected; HR, 0.76 (95% CI, 0.50 to 1.14) PIK3CA detected versus 0.80 (95% CI, 0.57 to 1.12) not detected.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 mutation prevalence by line of therapy
“ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote